ACLX News and Press, Arcellx Inc. From 11/02/23

Arcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 65th ASH Annual Meeting and Exposition PR Newswire -- Abstract released today is from a June 2, 2023 data cut -- -- Median duration of re...

Arcellx to Participate in Two Upcoming Investor Conferences PR Newswire REDWOOD CITY, Calif. , Oct. 26, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for p...

2023-10-23 02:50:39 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotechnology is the source of some of our strongest and growing revolutions. Gene technology allows us to cure incurable diseases and make miracles happen with living organisms. Immunotherapie...

2023-09-06 10:54:25 ET Summary Arcellx is a biotech firm developing advanced cell therapies for diseases like cancer, with a focus on their CART-ddBCMA program for multiple myeloma. Recent positive FDA developments have lifted the clinical hold on Arcellx's T-cell therapy for mult...

2023-08-21 20:10:21 ET Summary Legend Biotech's Carvykti has shown improved uptake in the second quarter. The company aims to reach an annualized capacity of 10,000 doses of Carvykti by the end of 2025. Reaching the late 2025 goal would translate to quarterly net sales of near...

2023-08-14 17:20:05 ET Arcellx press release ( NASDAQ: ACLX ): Q2 GAAP EPS of -$0.50. Revenue of $14.3M. For further details see: Arcellx GAAP EPS of -$0.50, revenue of $14.3M

Arcellx Announces Partial Clinical Hold Lifted on iMMagine-1 Phase 2 Clinical Program and Reports Second Quarter Financial Results PR Newswire -- Company expects to present preliminary data from iMMagine-1 study in 2H'24 -- REDWOOD CITY, Calif. , Aug. 14, 2023 ...

2023-07-26 07:00:00 ET Summary Baron Health Care Fund invests in companies engaged in the research, development, production, sale, delivery, or distribution of products and services related to the healthcare industry. In the quarter ended June 30, 2023, Baron Health Care Fund adva...

2023-06-21 07:00:30 ET Summary Arcellx's CART-ddBCMA program faces a clinical hold due to a patient's death, but the company plans to work with the FDA to amend the protocol. The company has a strong financial standing, a robust partnership with Kite Pharma, and promising treatmen...

Arcellx Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program PR Newswire -- FDA has provided clearance to the company to continue dosing patients who have already undergone lymphodepletion -- REDWOOD CITY, Calif. , June 19, 2023 /PRNews...